ClinicalTrials.gov
ClinicalTrials.gov Menu

Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients (RLS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00806026
Recruitment Status : Completed
First Posted : December 10, 2008
Results First Posted : September 27, 2012
Last Update Posted : September 27, 2012
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.

Condition or disease Intervention/treatment Phase
Idiopathic Restless Legs Syndrome Drug: placebo and pregabalin Drug: pramipexol Drug: Pregabalin Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 731 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome
Study Start Date : December 2008
Actual Primary Completion Date : May 2011
Actual Study Completion Date : May 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Restless Legs
Drug Information available for: Pregabalin

Arm Intervention/treatment
Experimental: PBO/PGB 300 mg Drug: placebo and pregabalin
following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
Other Name: Lyrica

Active Comparator: PBO/PPX 0.25 mg Drug: pramipexol
following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
Other Name: Mirapex

Active Comparator: PBO/PPX 0.5 mg Drug: pramipexol
following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
Other Name: Mirapex

Experimental: PGB 300 mg Drug: Pregabalin
pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Other Name: Lyrica

Active Comparator: PPX 0.25 mg Drug: pramipexol
pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Other Name: Mirapex

Active Comparator: PPX 0.5 mg Drug: pramipexol
pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Other Name: Mirapex




Primary Outcome Measures :
  1. Restless Legs Syndrome (RLS) Symptom Severity [ Time Frame: Baseline ]
    International Restless Legs Syndrome Study Group Rating Scale (IRLS) is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.

  2. Change From Baseline in the RLS Symptom Severity at Week 12 [ Time Frame: Baseline, Week 12 ]
    IRLS is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.

  3. Percentage of Participants Responding to Treatment at Week 12 [ Time Frame: Week 12 ]
    CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Responders were defined as participants who report CGI-I score of "very much improved" or "much improved".

  4. Percentage of Participants With Augmentation [ Time Frame: Baseline up to Week 52 ]
    Augmentation was worsening of RLS symptoms, attributable to a specific long-term therapeutic intervention for RLS. Percentage of participants with augmentation was evaluated by centralized evaluation board using a set of assessment criteria for potential augmentation which included structured interview for diagnosis of augmentation during RLS treatment (SIDA-RLS), augmentation severity rating scale (ASRS), clinical judgment. ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.


Secondary Outcome Measures :
  1. Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO) [ Time Frame: Baseline ]
    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.

  2. Change From Baseline in SSQ: Subjective WASO at Week 12 [ Time Frame: Baseline, Week 12 ]
    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.

  3. Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12 [ Time Frame: Week 12 ]
    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Latency subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Latency subscale score ranges from 0-840 minutes. Lower value indicates better sleep.

  4. Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12 [ Time Frame: Week 12 ]
    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Hours of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Hours of sleep subscale score ranges from 0-16 hours. Higher value indicates better sleep.

  5. Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12 [ Time Frame: Week 12 ]
    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Number of awakenings subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Number of awakenings subscale score ranges from 0-30. Lower value indicates better sleep.

  6. Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12 [ Time Frame: Week 12 ]
    SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Quality of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Quality of sleep subscale score ranges from 0-100. Higher score indicates better quality of sleep.

  7. RLS-Next Day Impact (RLS-NDI) [ Time Frame: Baseline ]
    The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.

  8. Change From Baseline in RLS-NDI at Week 12 [ Time Frame: Baseline, Week 12 ]
    The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.

  9. Limb Pain-Visual Analog Scale (Limb Pain-VAS) [ Time Frame: Baseline ]
    100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.

  10. Change From Baseline in Limb Pain-VAS at Week 12 [ Time Frame: Baseline, Week 12 ]
    100 mm line (VAS) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. Change = observation mean minus baseline mean.

  11. Severity of Augmentation Symptoms at Week 12 [ Time Frame: Week 12 ]
    ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.

  12. Clinical Global Impressions-Severity (CGI-S) at Week 12 [ Time Frame: Week 12 ]
    CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal-not ill at all) to 7 (among the most extremely ill participants). Higher score = more affected.

  13. Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 12 [ Time Frame: Week 12 ]
    MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Sleep adequacy data was reported at week 12 and not for first 12 weeks (average). Subscale scores range: 0-100; exception quantity of sleep (range 0-24 hours). With exception of sleep quantity and sleep adequacy, higher scores reflect poorer sleep outcomes.

  14. Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12 [ Time Frame: Week 12 ]
    MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/ headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Optimal sleep subscale scores range: 0-1; Optimal sleep = 1 if 'Average hours sleep' = 7 or 8, is 0 if 'Average hours sleep' is non-missing and less than 7, and is missing if 'Average hours sleep' is missing. Higher scores reflect better sleep outcomes.

  15. Profile of Mood State (POMS) at Week 12 [ Time Frame: Week 12 ]
    POMS are participant-rated instrument comprising 6 sub-scales (tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment) and each subscale comprising 5 items, on 'How you feel right now?' (Scale: 0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for vigor-activity. A total score is obtained for each scale. The range of total score is 0 - 100, with higher score indicating more mood disturbance.

  16. Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12 [ Time Frame: Week 12 ]
    RLS QoL: Participant rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life.

  17. Medical Outcomes Study-Short Form 36 (SF-36) at Week 12 [ Time Frame: Week 12 ]
    SF-36 is a standardized survey evaluating 8 aspects of functional health and well being (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health); 2 summary scores (physical and mental component); and self evaluated change in health status (summary of health status). The score for subscale scores and 2 summary score is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Summary of health status is a 5-point Likert scale ranging from "0=much worse now" to "4=much better now". Higher subscale and summary score reflect better health status.

  18. Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) at Week 12 [ Time Frame: Week 12 ]
    WPAI: 6 question participant rated questionnaire to determine degree to which SHP affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 10 (completely affected/impaired). WPAI outcomes expressed as impairment percentages with higher numbers indicating greater impairment and less productivity.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • idiopathic RLS with the presence of all four clinical manifestations of RLS
  • RLS symptoms occur predominantly in the evening
  • RLS history at least 6 months
  • IRLS => 15 at the beginning and the end of placebo run-in
  • Have =>15 nights with RLS symptoms in the month prior to screening

Exclusion Criteria:

  • Any secondary RLS
  • Current augmentation due to RLS treatment
  • Placebo responders identified during the placebo run-in

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00806026


  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209
Pfizer Investigational Site
Jasper, Alabama, United States, 35501
Pfizer Investigational Site
Tuscaloosa, Alabama, United States, 35406
United States, Arizona
Pfizer Investigational Site
Glendale, Arizona, United States, 85308
Pfizer Investigational Site
Phoenix, Arizona, United States, 85032
Pfizer Investigational Site
Phoenix, Arizona, United States, 85050
United States, Arkansas
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72205
Pfizer Investigational Site
Little Rock, Arkansas, United States, 72211
United States, California
Pfizer Investigational Site
Northridge, California, United States, 91325
Pfizer Investigational Site
Redondo Beach, California, United States, 90277
Pfizer Investigational Site
San Diego, California, United States, 92103
Pfizer Investigational Site
San Diego, California, United States, 92121
Pfizer Investigational Site
Santa Monica, California, United States, 90404
Pfizer Investigational Site
Torrance, California, United States, 90502
United States, Colorado
Pfizer Investigational Site
Aurora, Colorado, United States, 80012
United States, Florida
Pfizer Investigational Site
Boca Raton, Florida, United States, 33486
Pfizer Investigational Site
Hallandale Beach, Florida, United States, 33009
Pfizer Investigational Site
Miami, Florida, United States, 33143
Pfizer Investigational Site
Pembroke Pines, Florida, United States, 33026
Pfizer Investigational Site
South Miami, Florida, United States, 33143
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30342
United States, Kansas
Pfizer Investigational Site
Overland Park, Kansas, United States, 66212
United States, Kentucky
Pfizer Investigational Site
Louisville, Kentucky, United States, 40217
United States, Louisiana
Pfizer Investigational Site
Baton Rouge, Louisiana, United States, 70808
United States, Maryland
Pfizer Investigational Site
Chevy Chase, Maryland, United States, 20815
United States, Massachusetts
Pfizer Investigational Site
Newton, Massachusetts, United States, 02459
United States, Michigan
Pfizer Investigational Site
Southfield, Michigan, United States, 48034
United States, Minnesota
Pfizer Investigational Site
Minneapolis, Minnesota, United States, 55415
United States, New Jersey
Pfizer Investigational Site
Princeton, New Jersey, United States, 08540
United States, New York
Pfizer Investigational Site
New York, New York, United States, 10019
United States, North Carolina
Pfizer Investigational Site
Salisbury, North Carolina, United States, 28144-0000
Pfizer Investigational Site
Salisbury, North Carolina, United States, 28144
Pfizer Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45219
Pfizer Investigational Site
Columbus, Ohio, United States, 43210
United States, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73112
United States, Pennsylvania
Pfizer Investigational Site
Lafayette Hill, Pennsylvania, United States, 19444
United States, Texas
Pfizer Investigational Site
Austin, Texas, United States, 78731
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
Houston, Texas, United States, 77063
Pfizer Investigational Site
Plano, Texas, United States, 75093
United States, Washington
Pfizer Investigational Site
Walla Walla, Washington, United States, 99362
Austria
Pfizer Investigational Site
Innsbruck, Austria, A-6020
Pfizer Investigational Site
Linz, Austria, A-4021
Pfizer Investigational Site
Wien, Austria, 1090
Finland
Pfizer Investigational Site
Helsinki, Finland, 00420
Pfizer Investigational Site
Kuopio, Finland, 70210
Pfizer Investigational Site
Tampere, Finland, 33520
Pfizer Investigational Site
Turku, Finland, 20520
Germany
Pfizer Investigational Site
Achim, Germany, 28832
Pfizer Investigational Site
Bad Saarow, Germany, 15526
Pfizer Investigational Site
Berlin, Germany, 10117
Pfizer Investigational Site
Berlin, Germany, 10245
Pfizer Investigational Site
Berlin, Germany, 10365
Pfizer Investigational Site
Berlin, Germany, 10437
Pfizer Investigational Site
Berlin, Germany, 10629
Pfizer Investigational Site
Berlin, Germany, 10969
Pfizer Investigational Site
Berlin, Germany, 12163
Pfizer Investigational Site
Berlin, Germany, 12683
Pfizer Investigational Site
Berlin, Germany, 13156
Pfizer Investigational Site
Bochum, Germany, 44787
Pfizer Investigational Site
Bochum, Germany, 44805
Pfizer Investigational Site
Bremen, Germany, 28325
Pfizer Investigational Site
Dortmund, Germany, 44229
Pfizer Investigational Site
Dresden, Germany, 01307
Pfizer Investigational Site
Freiburg, Germany, 79106
Pfizer Investigational Site
Gelsenkirchen, Germany, 45879
Pfizer Investigational Site
Halle, Germany, 06118
Pfizer Investigational Site
Hamm, Germany, 59065
Pfizer Investigational Site
Jena, Germany, 07743
Pfizer Investigational Site
Juelich, Germany, 52428
Pfizer Investigational Site
Kassel, Germany, 34128
Pfizer Investigational Site
Kassel, Germany, 34131
Pfizer Investigational Site
Koethen, Germany, 06366
Pfizer Investigational Site
Leipzig, Germany, 04107
Pfizer Investigational Site
Marburg, Germany, 35039
Pfizer Investigational Site
Muenchen, Germany, 80331
Pfizer Investigational Site
Oldenburg, Germany, 26122
Pfizer Investigational Site
Prien, Germany, 83209
Pfizer Investigational Site
Schwerin, Germany, 19053
Pfizer Investigational Site
Siegen, Germany, 57072
Pfizer Investigational Site
Ulm, Germany, 89073
Pfizer Investigational Site
Ulm, Germany, 89081
Pfizer Investigational Site
Unterhaching, Germany, 82008
Pfizer Investigational Site
Westerstede, Germany, 26655
Pfizer Investigational Site
Wuerzburg, Germany, 97070
Italy
Pfizer Investigational Site
Pavia, Italy, 27100
Pfizer Investigational Site
Pisa, Italy, 56126
Pfizer Investigational Site
Rome, Italy, 00163
Pfizer Investigational Site
Rome, Italy, 00185
Pfizer Investigational Site
Troina(EN), Italy, 94018
Pfizer Investigational Site
Troina, Italy, 94018
Netherlands
Pfizer Investigational Site
Ede, Netherlands, 6716 RP
Pfizer Investigational Site
Zwolle, Netherlands, 8025 BV
Spain
Pfizer Investigational Site
Barcelona, Cataluña/Spain, Spain, 08003
Pfizer Investigational Site
Barcelona, Spain, 08035
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Granada, Spain, 18014
Pfizer Investigational Site
Madrid, Spain, 28036
Sweden
Pfizer Investigational Site
Avesta, Sweden, 77482
Pfizer Investigational Site
Avesta, Sweden, SE-774 82
Pfizer Investigational Site
Göteborg, Sweden, 40530
Pfizer Investigational Site
Göteborg, Sweden, 413 45
Pfizer Investigational Site
Orebro, Sweden, 701 85
Pfizer Investigational Site
Skovde, Sweden, 541 85
Pfizer Investigational Site
Skovde, Sweden, SE-541 85
Pfizer Investigational Site
Skövde, Sweden, 54185
Pfizer Investigational Site
Stockholm, Sweden, 11245
Pfizer Investigational Site
Örebro, Sweden, 70185
United Kingdom
Pfizer Investigational Site
Reading Berks, United Kingdom, RG2 0TG
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00806026     History of Changes
Other Study ID Numbers: A0081186
First Posted: December 10, 2008    Key Record Dates
Results First Posted: September 27, 2012
Last Update Posted: September 27, 2012
Last Verified: August 2012

Keywords provided by Pfizer:
RLS

Additional relevant MeSH terms:
Syndrome
Psychomotor Agitation
Restless Legs Syndrome
Disease
Pathologic Processes
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Parasomnias
Mental Disorders
Pregabalin
Pramipexole
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anticonvulsants
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs